Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Peytavin G, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2013 Oct 23;27(16):2655-7. doi: 10.1097/01.aids.0000432539.77711.f4.

PMID:
23939241
2.

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2015 Jan 2;29(1):53-8. doi: 10.1097/QAD.0000000000000516.

PMID:
25387314
3.

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

Liver Transpl. 2012 Dec;18(12):1464-70. doi: 10.1002/lt.23542.

4.

Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.

Marciano S, Galdame OA, Barcan LA, Gadano AC.

Acta Gastroenterol Latinoam. 2015 Mar;45(1):76-9.

PMID:
26076519
5.

A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.

Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.

J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006. Epub 2014 Jan 27.

PMID:
24477330
6.
7.

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M.

Liver Transpl. 2012 Sep;18(9):1053-9. doi: 10.1002/lt.23482.

8.

Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.

Farnik H, Zimmermann T, Herrmann E, Bechstein WO, Kronenberger B, Galle PR, Labocha S, Ferreiros N, Geisslinger G, Zeuzem S, Sarrazin C, Welker MW.

Liver Int. 2015 Jan;35(1):176-83. doi: 10.1111/liv.12532. Epub 2014 Apr 9.

PMID:
24649882
9.

Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.

Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A.

HIV Med. 2014 Feb;15(2):108-15. doi: 10.1111/hiv.12086. Epub 2013 Sep 11.

10.

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.

Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.

Ann Hepatol. 2013 Mar-Apr;12(2):228-35.

11.

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.

Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, Pialoux G, Benhamou Y, Thibault V, Katlama C.

AIDS. 2006 May 12;20(8):1157-61. Review.

PMID:
16691067
12.

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.

de Bruijne J, Sullivan JC, Kieffer TL, Botfield M, Shames B, Schinkel J, Molenkamp R, Weegink C, Reesink H.

J Clin Virol. 2012 Feb;53(2):174-7. doi: 10.1016/j.jcv.2011.11.004. Epub 2011 Dec 3.

PMID:
22138301
13.

Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.

Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, Piron M, Sauleda S, Len O, Pahissa A, Esteban R, Guardia J, Margarit C.

Antivir Ther. 2006;11(8):1061-70.

PMID:
17302376
14.

Management of hepatitis C in HIV infected and other immunocompromised individuals.

Seth AK.

Trop Gastroenterol. 2006 Jul-Sep;27(3):111-7. Review.

PMID:
17310553
15.

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.

Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, Lazzarin A, Uberti-Foppa C.

Int J Infect Dis. 2014 Dec;29:100-2. doi: 10.1016/j.ijid.2014.08.011. Epub 2014 Oct 24.

16.

Current management and perspectives for HCV recurrence after liver transplantation.

Coilly A, Roche B, Samuel D.

Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062. Review.

PMID:
23286847
17.

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.

De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G.

J Viral Hepat. 2013 Jun;20(6):395-403. doi: 10.1111/jvh.12046. Epub 2013 Jan 10.

PMID:
23647956
18.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
19.

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.

Al Nahdi N, Ford JA, Greanya ED, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, Yoshida EM.

Ann Hepatol. 2013 Jan-Feb;12(1):156-60.

20.

Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.

Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J.

Antiviral Res. 2013 Aug;99(2):119-24. doi: 10.1016/j.antiviral.2013.05.002. Epub 2013 May 14.

PMID:
23684903
Items per page

Supplemental Content

Write to the Help Desk